Serum antioxidant activity after myocardial infarction
Miller et al. measured total antioxidant activity (TAA) and the 'antioxidant gap' after myocardial infarction. I They reported that whereas no significant changes were observed in serum total antioxidant activity, a decline in the 'antioxidant gap' after myocardial infarction was associated with a significantly higher mortality. We would like to comment on the validity of their method of derivation of the 'antioxidant gap'.
To calculate the 'antioxidant gap', for each serum sample Miller et al. subtracted from TAA, the activity ascribable to albumin and uric acid. This involved measuring the serum concentrations of albumin and urate and multiplying these values by previously derived conversion factors of 0·69 per mmol/L for albumin and 1·0 per mmol/L for urate.?
The contribution made by albumin to TAA was also recently investigated in our laboratory using a Centrifree Micropartition System (Amicon) which retained proteins of molecular weight > 30 000. TAA was measured in serum samples before and after filtration. The albumin concentrations in serum samples pre and post-filtration were also measured. Furthermore, serial dilutions of albumin (Sigma) were prepared and analysed directly for antioxidant activity. Using both approaches, we calculated that the albumin contribution to the TAA was 0·90 per rnrnol/L, As such, our Furthermore, irrespective of the above potential discrepancy, it may be wholly inaccurate to assume that the in vivo antioxidative capacity of albumin remains constant at all times. Albumin is a major transport protein in the blood, and there occurs continuous fluctuations in the degree of binding of different compounds to its binding sites, e.g. during stress and in disease situations, all of which may alter its antioxidative capacity.
Therefore, we suggest that the discrepancy found between reported 1 and our experimental findings of the contribution from albumin/ albumin complexes to the total antioxidant activity needs to be investigated further, especially if the concept of antioxidant gap is to have any clinical value.
Letters C, the figures show there must be other contributory substances present, awaiting positive identification. Assessment of potential clinical usefulness will then surely depend on the identification of the specific antioxidants and their measurement where this is possible. In the mean time, there is some information to be gained from studying the changes in serum in oxidative stress states-it is very interesting to note, for example, that some neonates have a larger 'antioxidant gap' than we have observed in healthy adults and also that it is the 'gap' antioxidants which decline most rapidly in patients with poor survival after myocardial infarction. Changing the factor for albumin, as proposed by Drs Sattar and Blacklock, would reduce the size of the antioxidant gap (somewhat) but will not affect the incremental size or the direction of these changes.
I agree with these authors on the underrecognized importance of albumin as a plasma antioxidant and I look forward to the confirmation of their data in a full scientific paper.
NICHOLAS J MILLER
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Microalbuminuria in type 2 diabetic patients
Drs Friis and Pedersen1 describe a prospective study of a group of 46 non-protein uric Danish type 2 (non-insulin dependent) diabetic patients in whom the baseline prevalence of microalbuminuria was 35%. In this group, there was a high incidence of development of overt proteinuria of 35% during the mean 30 months follow-up period. In those patients with normal urinary albumin excretion rate (AER) at baseline, there was a high incidence of microalbuminuria developing (27% in the first year of observation). In contrast, among Danish type 2 diabetic patients with microalbuminuria, Mogensen? found an incidence of only 22% in the development of proteinuria in 10 years. Moreover, in a recent study of 176 Danish type 2 patients with initially normal AER, Gall et at.'
found a 5 year cumulative incidence of microalbuminuria of only 23%. The reasons for the exceptionally high incidence of microalbuminuria and proteinuria in Friis and Pedersen's study are unclear. In
Ann Clin Biochem 1998: 35 their original cross-sectional study," 98 type 2 diabetic patients were studied. We commented then on some of the factors that can lead to differences in microalbuminuria prevalence estimates between studies." The reader is informed that only 46 (47%) of these original 98 patients agreed to participate in the followup study (the remainder preferring to return to general practitioner care for their diabetes). No information is given of the differences between those who did and did not participate and there remains a possibility of patient selection bias.
In the cross-sectional study, antihypertensive therapy (AHT) was discontinued for a week, during which time AER was estimated. For the prospective study it is unclear how much of a confounding influence AHT had on AER estimates. Of the 16 patients with proteinuria at the end of the study, seven (44%) were free of retinopathy. Parving et al? have shown that as many as 50% of Danish type 2 diabetic patients with proteinuria but with no evidence of retinopathy may have non-diabetic renal disease. Because of the small number of patients included in Friis and Pedersen's study, any misclassification of albuminuria status or inclusion of patients with non-diabetic kidney disease might have had a significant effect on the estimated incidence of microalbuminuria and proteinuria.
